Image_3_HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma.png
Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells.
History
References
- https://doi.org//10.3322/caac.21387
- https://doi.org//10.1038/leu.2013.313
- https://doi.org//10.1080/10428194.2017.1386304
- https://doi.org//10.1016/S0140-6736%2819%2932956-3
- https://doi.org//10.1016/j.ctrv.2017.03.010
- https://doi.org//10.3390/antib6040018
- https://doi.org//10.3324/haematol.2018.194118
- https://doi.org//10.1074/jbc.M208268200
- https://doi.org//10.18632/aging.103858
- https://doi.org//10.1002/psc.3004
- https://doi.org//10.1016/S1470-2045%2814%2970442-5
- https://doi.org//10.1200/JCO.2005.04.242
- https://doi.org//10.1136/jitc-2020-000734
- https://doi.org//10.12659/MSM.923716
- https://doi.org//10.1158/2326-6066.CIR-18-0885
- https://doi.org//10.1038/35869
- https://doi.org//10.1089/mab.2018.0043
- https://doi.org//10.1080/2162402X.2018.1534664
- https://doi.org//10.1038/s41467-019-10335-5
- https://doi.org//10.1111/1756-185X.13027
- https://doi.org//10.1016/j.oooo.2016.12.002
- https://doi.org//10.1002/ajh.25117
- https://doi.org//10.1182/blood.2019000241
- https://doi.org//10.3389/fimmu.2018.02848
- https://doi.org//10.1111/cei.13292